Compared with untreated controls, tumour-bearing mice treated with navarixin—an orally bioavailable small-molecule antagonist of CXCR1/2—or with thrombospondin-1 (TSP-1), which simultaneously blocks CD47 on tumour cells and CD36 on macrophages, presented significantly reduced tumour volumes (Fig. 7A–B). This evidence concerns the gene CXCR1 and neoplasm.